IsomAb Appoints Dr Anker Lundemose as a Non-Executive Director
Commenting on the appointment, Paul Edwards, Chairman of IsomAb Ltd, said: "On behalf of the Board I am pleased to welcome Anker as an independent director. His expertise and his deep industry experience will be a valuable addition to our team of seasoned investors on the Board as well as to our CEO and executive team and we look forward to benefitting from his insights.
Dr Anker Lundemose, said: "I am very happy to join IsomAb Ltd as an independent director, and I look forward to working closely with my new board colleagues and the CEO to help the Company leverage its potential for the benefit of patients and the stakeholders. I have a long-standing interest in both metabolic and cardiovascular diseases and am excited about the potential of ISM-001 to bring real improvements in patient treatment in these fields.”
Anker Lundemose, who qualified with a medical degree from Aarhus University in Denmark, is currently Chief Executive Officer of MISSION Therapeutics in Cambridge, UK. He has extensive experience from business and corporate development as well as R&D in several key therapeutic areas including oncology, diabetes and anti-infectives. He has a comprehensive international experience and network and has been responsible for successful mergers and acquisitions within biotech, venture investments and licensing. His background includes biotech start-ups, large biotech and big pharma, as well as an initial career in academia.
-ENDS-
For further information please contact:
IsomAb Ltd
RHA Communications
Notes to Editors
About IsomAb Ltd
IsomAb Ltd, founded in 2022, is a UK-based biopharmaceutical company and is a spin-out from the University of Nottingham; early research was conducted at the University of Bristol and funding has been received from the British Heard Foundation, Wellcome Trust and the Medical Research Council. The Company was founded by Prof. David Bates and Prof. Steve Harper based on ground-breaking research into VEGF-A and its splice isoforms, and focusses on the development of isoform specific antibodies for disease modifying treatment of life limiting diseases with peripheral ischaemia. ISM-001 is high affinity, humanised antibody to restore blood flow in diabetic vascular disease. For more information, visit: www.isomab.bio.
